The impact of osteoporosis in men treated for prostate cancer

Urologic Clinics of North America

Volumn 31, Issue 2, 2004, Pages 313-319

  Oefelein, Michael G ^a   Resnick, Martin I ^a  

^a CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALENDRONIC ACID; ANTIANDROGEN; BISPHOSPHONIC ACID DERIVATIVE; CALCIUM; COLECALCIFEROL; DIETHYLSTILBESTROL; ESTROGEN; GONADORELIN AGONIST; POLYESTRADIOL PHOSPHATE; VITAMIN D; ZOLEDRONIC ACID;

BONE DENSITY; BONE MINERAL; BONE TURNOVER; DISEASE ASSOCIATION; FRAGILITY FRACTURE; HUMAN; MALE; ORCHIECTOMY; OSTEOPENIA; OSTEOPOROSIS; PRIORITY JOURNAL; PROSTATE CANCER; QUALITY OF LIFE; REVIEW; THROMBOEMBOLISM; VITAMIN SUPPLEMENTATION;

AGED; ANDROGEN ANTAGONISTS; ANTINEOPLASTIC AGENTS, HORMONAL; BONE DENSITY; DENSITOMETRY; DOSE-RESPONSE RELATIONSHIP, DRUG; FOLLOW-UP STUDIES; FRACTURES, SPONTANEOUS; HUMANS; INCIDENCE; MALE; MIDDLE AGED; ORCHIECTOMY; OSTEOPOROSIS; PROSTATIC NEOPLASMS; RISK ASSESSMENT;

EID: 2342509137     PISSN: 00940143     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ucl.2004.02.002     Document Type: Review

References (39)

1. WHO Study Group on Assessment of Fracture Risk and its Application to Screening for Postmenopausal Osteoporosis. Assessment of fracture risk and its application to screening for postmenopausal osteoporosis. 1994;World Health Organization, Geneva (Switzerland)
2. Raisz L.G., Kream B.E., Lorenzo J.A. Metabolic bone disease. Wilson J.D. William's textbook of endocrinology. 9th edition:1998;1211-1228 W.B. Saunders, Philadelphia
3. Marshall D., Johnell O., Wedel H. Meta-analysis of how well measures of bone mineral density predict occurrence of osteoporotic fractures. BMJ. 312:1996;1254-1261
4. Ross R.W., Small E.J. Osteoporosis in men treated with androgen deprivation therapy for prostate cancer. J Urol. 167:2002;1952-1956
5. Wei J.T., Gross M., Jaffe C.A., Gravlin K., Lahaie M., Faerber G.J., et al. Androgen deprivation therapy for prostate cancer results in significant loss of bone density. Urology. 54:1999;607-611
6. Smith M.R., McGovern F.J., Fallon M.A., Schoenfeld D., Kantoff P.W., Finkelstein J.S. Low bone mineral density in hormone-naive men with prostate carcinoma. Cancer. 91:2001;2238-2245
7. Berruti A., Dogliotti L., Tucci M., Tarabuzzi D., Fontana D., Angeli A. Metabolic bone disease induced by prostate cancer: rationale for the use of bisphosphonates. J Urol. 166:2001;2023-2031
8. Dowell D.J. Malignant bone resorption: cellular and biochemical mechanisms. Ann Oncol. 3:1992;257
9. Guise T.A., Mundy G.R. Cancer and bone. Endocr Rev. 19:1998;18
10. Urwin G.H., Percival R.C., Harris S. Generalised increase in bone resorption in carcinoma of the prostate. Br J Urol. 57:1985;721
11. Oefelein M.G., Ricchiuti V., Conrad W., Resnick M.I. Skeletal fractures negatively correlate with overall survival in men with prostate cancer. J Urol. 168:2002;1005-1007
12. Jackson J.A., Kleerekoper M. Osteoporosis in men: diagnosis, pathophysiology and prevention. Medicine. 69:1990;137
13. Kelepouris N., Harper K.D., Gannon F.M. Severe osteoporosis in men. Ann Intern Med. 123:1995;452
14. Seeman E., Melton L.K. Risk factors for spinal osteoporosis in men. Am J Med. 75:1983;977-983
15. Eriksson S., Eriksson A., Stege R., Carlstrom K. Bone mineral density in patients with prostatic cancer treated with orchidectomy and with estrogens. Calcif Tissue Int. 57:1995;97-99
16. Daniell H.W., Dunn S.R., Ferguson D.W., Lomas G., Niazi Z., Stratte T. Progressive osteoporosis during androgen depravation therapy for prostate cancer. J Urol. 163:2000;181-186
17. Melton L.J. III, Alothman K.I., Khosla S., Achenbach S.J., Oberg A.L., Zincke H. Fracture risk following bilateral orchiectomy. J Urol. 169:(5):2003;1747-1750
18. Maillefert J.F., Sibilia J., Michel F., Saussine C., Javier R.M., Tavernier C. Bone-mineral density in men treated with synthetic gonadotrophin-releasing hormone agonists for prostatic carcinoma. J Urol. 161:1999;1219
19. Stoch S.A., Parker R.A., Chen L., Bubley G., Ko Y.J., Vincelette A., et al. Bone loss in men with prostate cancer treated with gonadotropin-releasing hormone agonists. J Clin Endocrinol. 86:2001;2787-2791
20. Mittan D., Lee S., Miller E., Perez R.C., Basler J.W., Bruder J.M. Bone loss following hypogonadism in men with prostate cancer treated with GnRH analogs. J Clin Endocrinol Metab. 87:2002;3656-3661
21. Smith M.R., Fallon M.A., Goode M.J. Cross-sectional study of bone turnover during bicalutamide monotherapy for prostate cancer. Urology. 61:2003;127-131
22. Diamond T., Campbell J., Bryant C., et al. The effect of combined androgen blockade on bone turnover and bone mineral densities in men treated for prostate carcinoma. Cancer. 83:1998;1561
23. Wiren K., Orwoll E. Androgens and bone: basic aspects. Orwoll E. Osteoporosis in men. 1999;211-274 Academic Press, San Diego (CA)
24. Scherr D., Pitts W.R., Vaughan E.D. Diethylstilbesterol revisited: androgen deprivation, osteoporosis and prostate cancer. J Urol. 167:2002;535-538
25. Pitts W.R. Jr. Diethylstilbesterol revised: androgen deprivation, osteoporosis and prostate cancer. J Urol. 168:2002;2131-2132
26. Oefelein M.G., Ricchuiti V., Conrad W., Seftel A., Bodner D., Goldman H., et al. Skeletal fracture associated with androgen suppression induced osteoporosis: the clinical incidence and risk factors for patients with prostate cancer. J Urol. 166:(5):2001;1724-1728
27. Hedlund P.O., Henriksson P. Parenteral estrogen versus total androgen ablation in the treatment of advanced prostate carcinoma: effects on overall survival and cardiovascular mortality. The Scandinavian Prostate Cancer Group (SPCG)-5 Trial Study. Urology. 55:2000;328-333
28. Ockrim J.L., Lalani E.N., Laniado M.E., Carter S.C., Abel P.D. Transdermal estradiol therapy for advanced prostate cancer - forward to the past? J Urol. 169:2003;1735-1737
29. Kent J.R., Bischoff A.J., Arduino L.J. Estrogen dosage and suppression of testosterone levels in patients with prostatic carcinoma. J Urol. 109:1973;858-860
30. Smith M.R., Eastham J., Gleason D.M., Shasha D., Tchekmedyian S., Zinner N. Randomized controlled trial of zoledronic acid to prevent bone loss in men receiving androgen deprivation therapy for nonmetastatic prostate cancer. J Urology. 169:2003;2008-2012
31. Drugstore.com. Available at http://www.drugstore.com. Accessed June 2003.
32. Groot M.T., Boeken Kruger C.G.G., Pelger R.C.M., Uyl-de Groot C.A. Costs of prostate cancer, metastatic to the bone, in The Netherlands. Eur Urol. 43:2003;226-232
33. Wiefurt K.P., Yun L., Castel L.D., Timbie J.W., Glendenning A., Schulman K.A. The impact of skeletal-related events on health-related quality of life of patients with metastatic prostate cancer. Ann Oncol. 13:(Suppl 5):2002;180
34. Daniell H.W. Osteoporosis after orchiectomy for prostate cancer. J Urol. 157:1997;439-444
35. Townsend M.F., Sanders W.H., Northway R.O., Graham S.D. Bone fractures associated with luteinizing hormone-releasing hormone agonists used in the treatment of prostate cancer. Cancer. 79:1997;545-550
36. Berruti A., Dogliotti L., Bitossi R., et al. Incidence of skeletal complications in patients with bone metastatic cancer and hormone refractory disease: predictive role of bone resorption and formation markers evaluated at baseline. J Urol. 164:2000;1248-1253
37. Saad F., Gleason D.M., Murray R., Tchekmedyian S., Venner P., Lacombe L., et al. A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma. J Natl Cancer Inst. 94:2002;1458-1468
38. Kiebzak G.M., Beinart G.A., Perser K., Ambrose C.G., Siff S.J., Heggeness M.H. Under treatment of osteoporosis in men with hip fracture. Arch Intern Med. 162:2002;2217-2222
39. Orwoll E., Ettinger M., Weiss S., Miller P., et al. Alendronate for the treatment of osteoporosis in men. N Engl J Med. 343:2000;604-610